going off glp 1 cold turkey Doctors explain what really happens when you stop taking Ozempic and other GLP-1 drugs Quitting Soda? No Need to

Always follow your providers storage instructions

Adverse events such as diarrhea, constipation, nausea, and vomiting associated with the GLP-1 RAs overlap with those seen with cancer treatments, so the patient who is undergoing treatment with an emetogenic regimen for cancer will likely experience additional weight loss, which can lead to nutritional deficiencies, loss of lean muscle mass, and loss of bone mass

Weight Loss Comparison: Injectable Semaglutide (Wegovy 2.4 mg weekly): Average weight loss: 14.9% of body weight Duration: 68 weeks Patients losing 5%+: 86.4% Patients losing 10%+: 69.1% Patients losing 15%+: 50.5% Injectable Tirzepatide (Zepbound 15 mg weekly): Average weight loss: 22.5% of body weight Duration: 72 weeks Patients losing 5%+: 96% Patients losing 10%+: 89% Patients losing 15%+: 78% Patients losing 20%+: 63% Oral Semaglutide (Rybelsus 14 mg daily): Average weight loss: 3-5% of body weight Duration: 26-52 weeks depending on study Patients losing 5%+: Approximately 30-40% Patients losing 10%+: Less than 10% Patients losing 15%+: Rare Real-World Weight Loss Examples: Starting Weight: 250 pounds Starting Weight: 200 pounds Why Such a Big Difference

Preoperative Management: GLP-1RAs can be continued in patients without elevated risk

Results We included 39 pwIIH (mean age 33.6 years [SD 8.0], 92.3% female, median BMI 36.3 kg/m 2 [IQR 31.438.3]), with 13 patients being treated with GLP-1-RAs

Abbreviations MASLD : Metabolic dysfunction-associated steatotic liver disease MASH : Metabolic dysfunction-associated steatohepatitis T2DM : Type 2 diabetes mellitus GLP-1 RAs : Glucagon-like peptide-1 receptor agonists GIP : Glucose-dependent insulinotropic polypeptide GCG : Glucagon AACE : American Association of Clinical Endocrinology AASLD : American Association for the Study of the Liver Diseases F2 : Fibrosis grade 2 ABCD : Adiposity-based chronic diseases EASO : European Association for the Study of Obesity VAT : Visceral adipose tissue FFA : Free fatty acids HSC : Hepatic stellate cells FDA : Food and drug administration F3 : Fibrosis grade 3 AST : Aspartate aminotransferase ALT : Alanine aminotransferase GGT : Gamma-glutamyl transferase NAFLD : Non-alcoholic fatty liver-disease LFC : Liver fat content MRI-PDFF : Magnetic resonance imaging derived proton density fat fraction ELF : Enhanced liver fibrosis FIB-4 : Fibrosis-4 index F1 : Fibrosis grade 1 NAS : NAFLD activity score AE : Adverse event SAE : Serious adverse event EMA : European Medicine Agency FGF21 : Fibroblast growth factor 21 MetALD : Metabolic dysfunction and alcohol-related liver disease References Le MH, Le DM, Baez TC, Wu Y, Ito T, Lee EY, Lee K, Stave CD, Henry L, Barnett SD, Cheung R, Nguyen MH